U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT07485257) titled 'Molecular Profiling of MRI-PSMA PET Discordance in Prostate Cancer' on Dec. 10, 2025.
Brief Summary: MRI and PSMA-PET are highly sensitive imaging tools for prostate cancer, yet they often detect different lesions. These discordant findings pose clinical uncertainty because their biological significance is unclear. This project aims to molecularly characterize MRI-PSMA PET discordant lesions using high-quality biobanked samples from patients enrolled in an institutional study (NCT06187870). By integrating imaging and molecular data, the study will clarify whether these lesions represent indolent disease, aggressive subclones, or bi...